Utilizing the Transposon Vector to Enhance the Expression of Recombinant Erythropoietin in Chinese Hamster Ovary Cells

Subject Areas : Journal of Animal Biology

Reyhane Lohrasbi ¹ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )
Seyede Hoda Jazayeri ² ( Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran )
Abbas Daneshipour ³ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )
Zahra Halfinezhad ⁴ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )
Robabe Mohammadi ⁵ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )
Parisa Javidzade ⁶ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )
Amir Amiri-Yekta ⁷ ( Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran )

Received: 2023-10-06 Accepted : 2023-11-22 Published : 2024-06-01

Keywords: Transposon element, High-expression cell line, PiggyBac, Erythropoietin, Therapeutic recombinant protein, CHO DG44.,

Abstract :

In pharmaceutical biotechnology and recombinant protein production, due to the low efficacy of inserting the target gene into the host gene genome and its integration into the heterochromatin regions, which leads to the suppression of transcription as well as the instability of the expression of the desired sequence, achieving cells with highexpression is a challenge. To overcome the limitations transposons, which are mobile genetic elements and have the ability to cut and insert target fragments in certain regions of the genome with the “Cut and Paste” mechanism, are effective. This research aims to evaluate the effect of the PiggyBac transposon vector on the expression level of recombinant Erythropoietin (rEPO) protein and to find a cell line with high expression. First the optimized rEPO sequence based on CHO codon performance was cloned into the pOptiVECTM plasmid. To create the second expression vector, the EPO-IRES-DHFR fragment was inserted into the PB513B-1 plasmid, and then the homogenization steps in both vectors were confirmed using Colony PCR reaction, enzyme digestion, and Sanger sequencing. In order to create a stable cell line, both vectors were separately transfected into CHO DG44 cells and then screened. After confirming the insertion of the vectors into the genome of the target cell, the level of erythropoietin gene expression at the transcript and protein level was checked using qRT-PCR and western blotting tests, respectively, in two cell lines. The Real-Time PCR data indicate a 188-fold increase in erythropoietin gene transcript in the PB513B-1-EPO cell line compared to pOptiVEC-EPO. Additionally, the western blotting test's result confirmed the correct synthesis and secretion of this protein. Analysis of findings in this research revealed that the transposon element significantly increased the expression of the desired gene at the transcriptional level and had could create a cell line with high expression of the target protein.

References:

1. Barnes L.M., Bentley C.M., Dickson A.J. 2004. Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnology and Bioengineering, 85(2):115-121.
2. Barnes L.M., Bentley C.M., Dickson A.J. 2003. Stability of protein production from recombinant mammalian cells. Biotechnology and Bioengineering, 81(6):631-639.
3. Burnight ER, Staber JM, Korsakov P, Li X, Brett BT, Scheetz TE, 2012. A hyperactive transposase promotes persistent gene transfer of a piggyBac DNA transposon. Molecular Therapy-Nucleic Acids, 2012(1):50-62.
4. Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, Wong NS, 2009. A study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer? Biotechnology and Bioengineering, 102(4):1182-1196.
5. Dahodwala H., Lee K.H. 2019. The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Current Opinion in Biotechnology, 60:128-137.
6. Dehnavi E., Siadat S.O.R., Roudsari M.F., Khajeh K. 2016. Cloning and high-level expression of β-xylosidase from Selenomonas ruminantium in Pichia pastoris by optimizing of pH, methanol concentration and temperature conditions. Protein Expression and Purification, 124:55-61.
7. Domínguez Á., Fermiñán E., Sánchez M., González F.M., Pérez-Campo F.M., García S., 1998. Non-conventional yeasts as hosts for heterologous protein production. International Microbiology, 1(2):131-142.
8. Galvan D.L., Nakazawa Y., Kaja A., Kettlun C., Cooper L.J., Rooney C.M. 2009. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. Journal of Immunotherapy, 32(8):837.
9. Ghavim M., Abnous K., Arasteh F., Taghavi S., Nabavinia M.S., Alibolandi M., 2017. High level expression of recombinant human growth hormone in Escherichia coli: crucial role of translation initiation region. Research in Pharmaceutical Sciences, 12(2):168.
10. Grabherr R., Nilsson E., Striedner G., Bayer K. 2002. Stabilizing plasmid copy number to improve recombinant protein production. Biotechnology and Bioengineering, 77(2):142-147.
11. Grabundzija I., Irgang M., Mátés L., Belay E., Matrai J., Gogol-Döring A. 2010. Comparative analysis of transposable element vector systems in human cells. Molecular Therapy, 18(6):1200-1209.
12. Huang X., Guo H., Tammana S, Jung Y.C., Mellgren E., Bassi P. 2010. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Molecular Therapy, 18(10):1803-1813.
13. Kim C.H., Oh Y., Lee T.H. 1997. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene, 199(1-2):293-301.
14. Lalonde M.E., Durocher Y. 2017. Therapeutic glycoprotein production in mammalian cells. Journal of Biotechnology, 251:128-140.
15. Li Z.M., Fan Z.L., Wang X.Y., Wang T.Y. 2022. Factors affecting the expression of recombinant protein and improvement strategies in chinese Hamster ovary cells. Frontiers in Bioengineering and Biotechnology, 10:880155.
16. Makino T., Skretas G., Georgiou G. 2011. Strain engineering for improved expression of recombinant proteins in bacteria. Microbial Cell Factories, 10(1):1-10.
17. Meir Y.J., Weirauch M.T., Yang H.S, Chung P.C., Yu R.K., Wu S.C. 2011. Genome-wide target profiling of piggyBac and Tol2 in HEK 293: pros and cons for gene discovery and gene therapy. BMC Biotechnology, 11:1-19.
18. Muñoz-López M., García-Pérez J.L. 2010. DNA transposons: nature and applications in genomics. Current Genomics, 11(2):115-128.
19. Okumura T., Masuda K., Watanabe K., Miyadai K., Nonaka K., Yabuta M. 2015. Efficient enrichment of high-producing recombinant Chinese hamster ovary cells for monoclonal antibody by flow cytometry. Journal of Bioscience and Bioengineering, 120(3):340-346.
20. Peng C., Shi C., Cao X., Li Y., Liu F., Lu F. 2019. Factors influencing recombinant protein secretion efficiency in gram-positive bacteria: signal peptide and beyond. Frontiers in Bioengineering and Biotechnology, 7(139):1-9.
21. Ritacco F.V., Wu Y., Khetan A. 2018. Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies. Biotechnology Progress, 34(6):1407-1426.


22. Sandoval-Villegas N., Nurieva W., Amberger M., Ivics Z. 2021. Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering. International Journal of Molecular Sciences, 22(10):5084-5113.
23. Stach C.S., McCann M.G., O’Brien C.M., Le T.S., Somia N., Chen X., 2019. Model-driven engineering of N-linked glycosylation in Chinese hamster ovary cells. ACS Synthetic Biology, 8(11):2524-2535.
24. Walsh G. 2018. Biopharmaceutical benchmarks 2018. Nature Biotechnology, 36(12):1136-1145.
25. Wang T.Y., Guo X. 2020. Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systems. Applied Microbiology and Biotechnology, 104(13):5673-5688.
26. Wei M., Mi C.L., Jing C.Q., Wang T.Y. 2022. Progress of transposon vector system for production of recombinant therapeutic proteins in mammalian cells. Frontiers in Bioengineering and Biotechnology, 10:879222.
27. Wilson M.H., Coates C.J., George A.L. 2007. PiggyBac transposon-mediated gene transfer in human cells. Molecular Therapy, 15(1):139-145.
28. Wurm F.M. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology, 22(11):1393-1398.
29. Yang Y., Chusainow J., Yap M.G. 2010. DNA methylation contributes to loss in productivity of monoclonal antibody-producing CHO cell lines. Journal of Biotechnology, 147(3-4):180-185.